The abstract is read at the publisher; the summary is JClub's.
Circulating extracellular vesicles enriched for PD-1, PD-L1, and CTLA-4 predict anti-PD-L1 therapy response and survival in advanced hepatocellular carcinoma, with resistance emerging 36–42 weeks before imaging.
- Why it matters: Only about 30% of hepatocellular carcinoma patients respond to first-line immune checkpoint inhibitor therapy, and routine tissue sampling is limited, creating a need for liquid-biopsy biomarkers.
- What they did: Using multiplex immunoassays, the study profiled immune checkpoints on circulating EVs in three cohorts (n=40, n=37, and n=202 with sequential samples), comparing ICI training (n=79) and validation (n=82) versus a TKI-treated group (n=41).
- The result: Baseline and early EV-IC dynamics discriminated responders from non-responders and predicted progression-free survival and overall survival in the ICI cohorts, but were not reproducible in the TKI cohort; EV-IC changes also flagged acquired resistance 36–42 weeks before imaging.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.